Ramya Gorthi, MD
Pulmonary Disease · Green Bay, WINPI 1578946455
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (48.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 84.0% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $4,054, more than ten times the $293 reported in 2019.
Across 32 payments — averaging $192.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- United Therapeutics Corporation$148
- AstraZeneca$142
- Genentech USA, Inc.$130
- Abiomed$125
- Actelion Pharmaceuticals US, Inc.$122
- plus $315 from 9 others
What the payments were for
- Travel & lodging$1,67227%
- Food & beverage$1,48324%
- Education$3,00049%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $5,173 |
| United Therapeutics Corporation | 1 | $148 |
| AstraZeneca | 2 | $142 |
| Genentech USA, Inc. | 1 | $130 |
| Abiomed | 1 | $125 |
| Actelion Pharmaceuticals US, Inc. | 1 | $122 |
| La Jolla Pharmaceutical Company | 1 | $79 |
| GSK | 4 | $71 |
| Covis Pharma GmbH | 2 | $40 |
| Boehringer Ingelheim | 1 | $30 |
| Grifols USA, LLC | 1 | $23 |
| Biogen | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Baxter Healthcare | 1 | $18 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,155 in reported general payments places this provider in the 80th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 237 | $188,133 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 149 | $74,007 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 94 | $63,115 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 64 | $61,797 |
| Spiriva RespimatTiotropium Bromide | 46 | $31,178 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $24,401 |
| Sildenafil Citrate | 13 | $18,492 |
| SymbicortBudesonide/Formoterol Fumarate | 57 | $14,871 |
| Spiriva HandihalerTiotropium Bromide | 20 | $13,221 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $6,453 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 48 | $6,143 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,639 |
| Varenicline Tartrate | 14 | $4,253 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 142 | $3,931 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $3,804 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $71 | $292,994450 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $30 | $99,932152 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $142 | $76,668121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 247 pulmonary disease providers in Wisconsin.
Other pulmonary disease in Green Bay
- Manar Al ShahrouriGreen Bay$61K
- Prince NtiamoahGreen Bay$37K
- Musab NusratGreen Bay$12K
- Jeremy RenzGreen Bay$10K
- Fazal RaziqGreen Bay$8K
- Raul Mendoza AyalaGreen Bay$7K
- Pamela SudGreen Bay$4K
- Jonathan KurmanMilwaukee$803K
- Mouhammed RihawiMilwaukee$713K
- Hasnain BawaadamKenosha$686K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.